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The etiology of gastrointestinal tumors implicates a role for chronic inflammation in response to pathogenic
microflora as a promoting force for full neoplastic progression. Recently, Oguma and coworkers (2008) dem-
onstrated that TNFa, derived from recruited macrophages, potentiates Wnt/b-catenin signaling and gastric
carcinogenesis by activating Akt signaling and GSK3b phosphorylation independent of the NF-kB pathway in
initiated epithelial cells. These observations provide a missing link in the mechanism whereby chronic inflam-
mation, in response to Helicobacter, regulates the ‘‘penetrance’’ of initiating oncogenic mutations in the
gastrointestinal tract leading to gastrointestinal tumorigenesis.Epidemiologic studies have long sup-
ported a link between chronic inflamma-
tion and development of solid tumors
(Coussens and Werb, 2002; Thun et al.,
2004). More recently, through utilization
of immunocompetent mouse models of
multistage carcinogenesis, the molecular
mechanisms whereby chronic engage-
ment of the immune system (inflamma-
tion) potentiates development of epithelial
cancers have begun to be elucidated
(Balkwill et al., 2005; de Visser et al.,
2006; Karin et al., 2006). Missing, how-
ever, has been insight into which soluble
mediators derived from chronically acti-
vated immune cells are significant for
regulating the penetrance of neoplastic
cells harboring initiating mutations. For
example, in the gastrointestinal tract,
malignancy is frequently preceded by
chronic inflammation sometimes associ-
ated with Helicobacter pylori infection
(Blaser, 2000) or in individuals harboring
activating mutations in the APC or
CTNNB1 genes or enhanced activation
of Wnt/b-catenin signaling (Clements
et al., 2002).
APC is a multifunctional cytoplasmic
protein whose gene is frequently mutated
in several types of gastrointestinal can-
cers. APC regulates both genomic insta-
bility and hyperactivation of the Wnt/
b-catenin signaling pathway, and nuclear
b-catenin accumulation is found in colon
carcinoma cells at invasive fronts (Fodde
and Brabletz, 2007). Recent experimental
studies have revealed that malignant con-
version of initiatedAPCmutant cells is po-
tentiated by chronic activation of the Wnt/
b-catenin signaling pathway (Fodde and
Brabletz, 2007); however, links between
these molecular mediators and chronic
inflammation have not been previously
identified.
Oguma and coworkers (2008) investi-
gated this link and found that both
enhanced Wnt expression and infection
by gastric microflora induce submucosal
infiltration by macrophages secreting high
levels of tumor necrosis factor-alpha
(TNFa). Binding of TNFa to TNF receptors
on gastric epithelial cells enhances Akt
phosphorylation that in turn induces gly-
cogen synthase kinase 3b (GSK3b) phos-
phorylation, resulting in stabilization and
nuclear accumulation of b-catenin that
potentiates gastric carcinogenesis (Fig-
ure 1). To reveal this pathway, the authors
utilized a mouse model of gastric tumori-
genesis in which Wnt1 is expressed in
gastrointestinal mucosal epithelia, K19-
Wnt1 transgenic mice, which develop
sporadic dysplastic lesions in the glandu-
lar stomach, mimicking hyperactivation
of Wnt/b-catenin signaling commonly ob-
served in patients with gastric carcinomaCancer Cell 14, July 2008 ª2008 Elsevier Inc. 7
Cancer Cell
PreviewsFigure 1. Macrophage-Derived TNFa Activates Wnt/b-Catenin during Gastrointestinal Cancer Development
Oncogenic mutations in tumor suppressors such as APC (APC*) are often associated with hyperactivation of Wnt/b-catenin pathways and stabilization of
b-catenin. However, when such mutations occur in gastrointestinal cells, additional stimuli are required for translocation of b-catenin to the nucleus. Chronic
inflammatory responses to pathogenic microflora such as Helicobacter can provide these stimuli via inducing macrophage infiltration. In response to bacterial
components such as LPS or TLR ligands, macrophages produce TNFa, which in turn promotes nuclear accumulation of dephosphorylated b-catenin mediated
by phosphoregulation of Akt and GSK3b in neoplastic epithelial cells in an NF-kB-independent manner. This process can be further exasperated by production of
Wnt ligands by stromal cells that bind Frizzled receptors, leading to inhibition of the b-catenin degradation complex (APC, AXIN, GSK3b), thereby enabling nuclear
translocation of stabilized b-catenin and transcriptional activation of Wnt target genes.(Oshima et al., 2006). In K19-Wnt1 mice,
macrophages accumulate in dysplastic
areas of the glandular stomach adjacent
to epithelia with nuclear accumulation of
b-catenin, thus supporting a potential
role for macrophages in regulating Wnt/
b-catenin signaling. To functionally ad-
dress this, the authors investigated a
second model of gastrointestinal tumori-
genesis, ApcD716 mice, in which activation
of Wnt/b-catenin signaling leads to devel-
opment of intestinal polyps. By inter-
crossing ApcD716 mice with op/op mice
that have impaired colony-stimulating
factor 1 (CSF1) signaling and decreased
macrophage infiltration in tissues, the
authors found a significant reduction in
intestinal polyp formation, reduced levels
of TNFa, and decreased Wnt/b-catenin
activity that was largely due to inhibition
of GSK3b and reduced Akt phosphoryla-
tion in gastric cancer cells.
To reveal whether this pathway is poten-
tiated by infection, Wnt1 transgenic mice
were infected with Helicobacter felis—
inflamed mucosa was histologically dis-
tinct from that found in dysplastic lesions
of noninfected gut. Infected animals rapidly
exhibited increased b-catenin accumula-
tion in proliferating epithelial cells and
decreased presence of H+/K+-ATPase-
positive parietal cells, thus indicating that
infection and inflammation promote Wnt/
b-catenin signaling and suppress epithelial
differentiation. Taken together, the results
of the study by Oguma and coworkers
(2008) reveal a new pathway whereby
chronic infection of the gastrointestinal
tract and the ensuing inflammatory micro-
environment facilitate expansion of initi-
ated cells by collaborating with existing
oncogenic mutations in epithelia.
The tumor-promoting capability of
macrophages has previously been dem-
onstrated using a mouse model of8 Cancer Cell 14, July 2008 ª2008 Elsevier Inc.
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Previewsmammary carcinogenesis in which infil-
tration of macrophages into premalignant
mammary tissue regulates mammary tu-
morigenesis (reviewed in Lin and Pollard,
2007). Failure to recruit macrophages
into malignant tissue significantly delays
development of late-stage carcinomas
and attenuates pulmonary metastasis,
likely via angiogenic mechanisms and
altered paracrine interactions between
epidermal growth factor (EGF) and CSF1
signaling pathways (Lin and Pollard,
2007). In breast and ovarian cancer,
TNFa provided by tumor-infiltrating mac-
rophages also promotes proinvasive phe-
notypes of neoplastic cells as well as
potentiating metastatic spread in ovarian
and hepatocellular cancer (Balkwill et al.,
2005). The present study by Oguma
et al. (2008) describes an additional
tumor-promoting role for macrophages,
independent of NF-kB-regulated path-
ways in epithelia, by providing a link
between the proinflammatory cytokine
TNFa and Wnt/b-catenin signaling.
In view of recent insights into mecha-
nisms whereby microbial infections pro-
mote tumor development (Karin et al.,
2006), it is intriguing that Helicobacter-
associated inflammation promotes Wnt/
b-catenin activity in initiated gastric
epithelium since it raises the possibility
that immune mediators directly influence
stem cell niche expansion or ‘‘stemness’’
during gastric tumorigenesis. Cells of the
gastrointestinal epithelium have a high
turnover rate (3–6 days) whereby the bal-
ance between apoptosis, senescence,
proliferation and differentiation is tightly
regulated to maintain tissue homeostasis.
Gastrointestinal epithelia are regenerated
from stem cell populations residing in
specific niches within the epithelium.
Due to their relatively rapid turnover rate,
differentiated gastrointestinal epithelia
are not believed to persist long enough
to acquire multiple genetic mutations
that might be necessary for full malig-
nancy before being shed into the lumen
and/or undergoing apoptosis; thus, it
has been postulated that gastrointestinal
malignancies originate from stem cell
populations. Wnt-regulated pathways
are important for homeostatic stem cell
renewal and are frequently upregulated
during gastrointestinal carcinogenesis
(Fodde and Brabletz, 2007). In addition
to TNFa, macrophages have also been
shown to directly produce Wnt ligands,
including Wnt2 and Wnt5a in human colo-
rectal tumors, further supporting a link
between macrophages and activation of
Wnt signaling pathways (Smith et al.,
1999). It is unclear from the Oguma et al.
(2008) study whether expression of Wnt
ligands is also upregulated in stromal
cells following Helicobacter infection, or
whether Wnt ligands derived from macro-
phages act synergistically with TNFa to
upregulate Wnt/b-catenin signaling. Con-
sidering the importance of Wnt signals
during gastric carcinogenesis, it is tempt-
ing to speculate that chronically engaged
immune cells may play a role in stem cell
niche expansion during gastric tumori-
genesis. In this manner, stem cell popula-
tions harboring initiating oncogenic or
tumor suppressor gene mutations, such
as APC, when present in a chronic inflam-
matory microenvironment might be sub-
ject to promotion-type events involving
TNFa and/or Wnt ligands, leading to tis-
sue expansion without differentiation,
and in so doing might provide an ex-
panded stem cell or stem cell-like popula-
tion at risk for acquiring secondary tumor-
promoting mutations. Thus, the findings
of Oguma et al. (2008) provide a mecha-
nism whereby Helicobacter-associated
inflammation may facilitate expansion of
initiated stem cells by promoting Wnt/
b-catenin signaling and thereby promot-
ing full neoplastic progression of initiated
cells by nourishing the roots of cancer
development.
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